氧气驱动雾化与超声雾化在慢性心力衰竭合并肺部感染患者中的临床应用

Clinical application of oxygen-driven atomization and ultrasonic atomization in patients with chronic heart failure and pulmonary infection

目的探讨氧气驱动雾化与超声雾化在慢性心力衰竭合并肺部感染患者中的临床应用效果。方法126例慢性心力衰竭合并肺部感染患者,随机分为观察组与对照组,每组63例。两组患者入院后均给予常规利尿、抗感染、扩血管等常规治疗,对照组患者给予超声雾化盐酸氨溴索口服溶液(商品名:沐舒坦)治疗,观察组患者给予氧气驱动雾化沐舒坦治疗。比较两组患者治疗前后临床指标、临床症状消失时间、治疗效果。结果治疗后,两组患者心率、收缩压、舒张压均较本组治疗前降低,血氧饱和度较本组治疗前升高,且观察组患者心率(95.24±3.44)次/min、收缩压(109.57±8.42)mm Hg(1 mm Hg=0.133 kPa)、舒张压(82.11±4.1)mm Hg低于对照组的(105.36±5.42)次/min、(135.04±10.63)mm Hg、(85.14±4.54)mm Hg,血氧饱和度(95.17±3.51)%高于对照组的(90.51±3.42)%,差异具有统计学意义(P<0.05)。观察组患者咳嗽、咳痰及肺部啰音消失时间短于对照组,差异具有统计学意义(P<0.05)。观察组患者治疗总有效率为95.2%(60/63),高于对照组的79.4%(50/63),差异具有统计学意义(P<0.05)。结论氧气驱动雾化与超声雾化沐舒坦均能改善慢性心力衰竭合并肺部感染患者的呼吸道症状,且氧气驱动雾化对患者心率、氧饱和度等的改善效果优于超声雾化,临床治疗效果显著。

Objective To discuss the clinical effect of oxygen-driven atomization and ultrasonic atomization in patients with chronic heart failure and pulmonary infection.Methods A total of 126 patients with chronic heart failure and pulmonary infection were randomly divided into observation group and control group,with 63 cases in each group.After admission,both groups were given conventional treatments such as diuresis,antiinfection,and vasodilation.The control group was treated with ultrasonic atomization of ambroxol hydrochloride oral solution(trade name:Mucosultan),and the observation group was treated with oxygen-driven atomization of Mucosultan.The clinical indicators and disappearance of clinical symptoms before and after treatment,and the therapeutic effect were compared between the two groups.Results After treatment,the heart rate,systolic blood pressure,and diastolic blood pressure of the two groups were lower than those of this group before treatment,and the blood oxygen saturation was higher than that of this group before treatment;the heart rate(95.24±3.44)beats/min,systolic blood pressure(109.57±8.42)mm Hg(1 mm Hg=0.133 kPa),and diastolic blood pressure(82.11±4.1)mm Hg of the observation group were lower than(105.36±5.42)beats/min,(135.04±10.63)mm Hg,(85.14±4.54)mm Hg of the control group,and the blood oxygen saturation(95.17±3.51)% was higher than(90.51±3.42)% of the control group;all differences were statistically significant(P<0.05).The disappearance time of cough,sputum and lung rales in the observation group was shorter than those in the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 95.2%(60/63),which was higher than 79.4%(50/63)in the control group,and the difference was statistically significant(P<0.05).Conclusion Both oxygen-driven atomization and ultrasonic atomization of Mucosolvan can improve the respiratory symptoms of patients with chronic heart failure and pulmonary infection,and the improvement of heart rate and oxygen saturation by oxygen-driven atomization is better than that by ultrasonic atomization,and the clinical effect is significant.